Clinical Trials | December 03, 2025
Merck unveils first human data for Alzheimer’s candidates
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Roche says the move marks a step forward in its digital transformation strategy
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Subscribe To Our Newsletter & Stay Updated
